| 名稱 | PIK3CA p.E545D Reference Standard |
| 型號(hào) | CBP10623 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | PIK3CA p.E545D Reference Standard |
產(chǎn)品搜索
相關(guān)文章
- 基于納米顆粒的組合免疫療法對(duì)致命性癌癥發(fā)起三重打擊
- 【靶點(diǎn)模型+診斷質(zhì)控】BCR-ABL1的藥物開發(fā)和診斷
- 有關(guān)腫瘤細(xì)胞的基因突變研究講解
- 百時(shí)美免疫組合治療非小細(xì)胞肺癌展現(xiàn)驚人療效
- 雙面PD1，Blocker已成卷王，agonist賽道你上車了嗎？
- IL36靶點(diǎn)藥物細(xì)胞篩選模型藥
- CYP2C19基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- 偏頭痛治療靶點(diǎn)——CGRP與藥篩細(xì)胞模型
- 一個(gè)蛋白竟可同時(shí)影響乳腺癌和淋巴癌的形成與擴(kuò)散
- Science：腫瘤非整倍體與癌癥免疫療法反應(yīng)下降相關(guān)聯(lián)
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
基因檢測(cè)標(biāo)準(zhǔn)品 > Mutation > CBP10623PIK3CA p.E545D Reference Standard
- 詳細(xì)內(nèi)容
CBP10623 | |
| Format | Genomic DNA |
| Description | PIK3CA E545D is a hotspot mutation that lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E545D results in increased transformation ability in two different cell lines in culture, and therefore, is predicted to lead to a gain of Pik3ca protein function. |
| Technical Data | |
| DNA Change: | c.1635G>T |
| AA Change | p.E545D |
| Mutation type | Substitution - Missense |
| Zygosity | Heterozygous |
| Allelic Frequency | N/A |
| Transcript | NM_006218.4 |
| Chr position(GRCh37) | chr3:178936093 |
| Buffer: | Tris-EDTA |
| Product Information | |
| Intended Use | Research Use Only |
| Unit Size | 1ug |
| Concentration | Download for COA |
| Purofication | Download for COA |
| DNA electrophoresis | Download for COA |
| Sanger sequencing |
|
| Storage | 4℃ |
| Expiry | 36 months from the date of manufacture |
" _ue_custom_node_="true">
會(huì)員_a.png)